Evidence map›Paper›PMID 38858662›Full record

ArticleBMC cancer2024

Prognostic marker VPS72 could promote the malignant progression of prostate cancer.

Xiaolong Xu, Wei Wang, Yi He, Yiqun Yao, Bo Yang

Abstract read
In one paragraph

Article in BMC cancer, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Xiaolong Xu *Department of Urology, the Second Affiliated Hospital of Dalian Medical University, 467, Zhongshan Road, Shahekou District, Dalian, Liaoning, 116001, China.
Wei Wang *Department of Urology, the Second Affiliated Hospital of Dalian Medical University, 467, Zhongshan Road, Shahekou District, Dalian, Liaoning, 116001, China.
Yi HeDepartment of Urology, the Second Affiliated Hospital of Dalian Medical University, 467, Zhongshan Road, Shahekou District, Dalian, Liaoning, 116001, China.
Yiqun YaoDepartment of Breast and Thyroid Surgery, the Affiliated Zhongshan Hospital of Dalian University, 6, Jiefang Street, Zhongshan District, Dalian, Liaoning, 116001, China. yaoyiqun_rx@163.com.
Bo YangDepartment of Urology, the Second Affiliated Hospital of Dalian Medical University, 467, Zhongshan Road, Shahekou District, Dalian, Liaoning, 116001, China. yangbo20160101@163.com.

Funding

"1+X" program for Clinical Competency enhancement-Clinical Research Incubation Project and the Second Hospital of Dalian Medical University 2022LCYJYB08"1+X" program for Clinical Competency enhancement-Clinical Research Incubation Project and the Second Hospital of Dalian Medical University 2022LCYJZD02the cultivating scientific research project of the Second Hospital of Dalian Medical University dy2yynpy202217
6 · The paper itself

Abstract

backgroundThis paper attempted to clarify the role and mechanism of vacuolar protein sorting-associated protein 72 homolog (VPS72) in the progression of prostate cancer (PCa).

methodsClinical information and gene expression profiles of patients with prostate cancer were obtained from The Cancer Genome Atlas (TCGA). VPS72 expression in PCa and the potential mechanism by which VPS72 affects PCa progression was investigated. Next, we performed COX regression analysis to identify the independent prognostic factors of PCa, and constructed a nomogram. The sensitivity of chemotherapeutic medications was anticipated using "pRRophetic". Subsequently, in vitro assays to validate the effect of VPS72 on PCa cell proliferation, migration and susceptibility to anti-androgen therapy.

resultsThe expression of VPS72 was considerably higher in PCa tissues compared to normal tissues. Significant correlations were found between high VPS72 expression and a poor prognosis and adverse clinicopathological factors. The nomogram model constructed based on VPS72 expression has good predictive performance. According to GSEA, VPS72-related genes were enriched in the NF-kB pathways, cytokine-cytokine receptor interaction and chemokine signaling pathway in PCa. Although PCa with low VPS72 expression was more adaptable to chemotherapeutic medications, our in vitro experiment showed that VPS72 knockdown significantly decreased the PCa cell migration, proliferation, and resistance to anti-androgen therapy.

conclusionsIn summary our findings suggests that VPS72 could play a crucial role in the malignant progression of PCa, and its expression level can be employed as a possible biomarker of PCa prognosis.

Indexed as

Biomarkers, TumorCell ProliferationDisease ProgressionProstatic NeoplasmsAgedAndrogen AntagonistsCell Line, TumorCell MovementGene Expression Regulation, NeoplasticHumansMaleMiddle AgedNomogramsPrognosisRepressor ProteinsVesicular Transport ProteinsAndrogen AntagonistsBiomarkers, TumorRepressor ProteinsVesicular Transport ProteinsVPS72 protein, humanClinical prognosisNomogramProstate cancerVPS72

Identifiers

PMID38858662
PMCPMC11163694

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.